Market Overview

Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts


Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is positioned to dominate a “blockbuster market,” according to Goldman Sachs. But while the bank believes in the biotech’s longer-term prospects, it sees no near-term catalysts for Madrigal’s stock.

The Rating

Analyst Salveen Richter downgraded Madrigal to Neutral but maintained his $314 price target.

The Thesis

Richter forecasts limited upside to his fundamental discounted cash flow value and anticipates few value-driving catalysts in the near future. However, he maintains high expectations for MGL-3196.

“We continue to view MGL-3196, a once-daily oral thyroid hormone receptor (THR)-beta agonist, as a best-in-class and industry drug for NASH driven by the positive liver and cardiometabolic profile (per the Phase 2 36-week study) and corroborating KOL feedback,” Richter wrote in a note. “Specifically, based on the efficacy/safety profile seen to date with MDGL’s MGL-3196 - our KOLs suggest this would be a first choice as monotherapy.”

He identifies a “clear development path” for MGL-3196 and anticipates New Drug Applications for two indications with global peak sales of $6 billion.

Additionally, given management’s interest in business development activities to commercialize the candidate, Madrigal could eventually drive value with a merger.

“Post the highly impressive MGL-3196 Ph2 36-week liver biopsy data, MDGL is positioned as a leading next-generation NASH player with a best-in-class strategic asset in a blockbuster market where there are currently no approved therapies,” Richter wrote.

Price Action

At time of publication, shares traded down 3.5 percent at $242.05.

Related Links:

Galmed Notches Second Bullish Rating On Aramchol Opportunity

Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal

Posted-In: Goldman Sachs Salveen RichterAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (MDGL)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Preview: Aircastle

The Legacy Of Outgoing PepsiCo CEO Indra Nooyi